Suvecaltamide

– Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects continued top- and bottom-line growth – DUBLIN , Feb. 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025. "2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total revenues of over $4 billion . Our diversified portfolio spanning sleep1, epilepsy and oncology, with each annualizing at over $1 billion , continued to drive growth," said Bruce Cozadd , chairman and chief executive officer, Jazz Pharmaceuticals . "We are pleased with the continued progress of our late-stage pipeline assets, including the recent launch of Ziihera in 2L HER2+ (IHC3+) BTC, upcoming top-line data readout from the HERIZON-GEA-01 trial in 1L GEA, which we now expect in the second half of 2025, and highly encouraging results from the Phase 3 IMforte trial, which we expect to submit as part of an sNDA for Zepzelca® in 1L ES-SCLC in the first half of 2025." Mr. Cozadd continued, "The strength of our 2024 results reinforces our confidence that Jazz is well-positioned to deliver top- and bottom-line growth in 2025 and drive long-term shareholder value. Our focus remains on disciplined capital allocation, which we expect to drive growth of our diversified commercial portfolio, continue advancement of our pipeline and provide flexibility to remain active in corporate development." Key Highlights Total revenues in 2024 grew 6% year-over-year; generated over $1.4 billion in cash from operations. Zanidatamab: Received U.S. FDA approval of and launched Ziihera in 2L HER2+ (IHC3+) BTC. Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 2H25. On track to submit an sNDA in 1H25 for Zepzelca in combination with Tecentriq® (atezolizumab) as maintenance therapy in 1L ES-SCLC based on the potentially practice-changing results from the Phase 3 IMforte trial. Top- and bottom-line growth expected in 2025; 2025 total revenue guidance of $4.15 - $4.40 billion , representing 5% growth at the midpoint. Total revenue guidance is underpinned by expected continued growth in diversified commercial portfolio spanning sleep1, epilepsy and oncology. Received U.S. FDA approval of and launched Ziihera in 2L HER2+ (IHC3+) BTC. Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 2H25. Total revenue guidance is underpinned by expected continued growth in diversified commercial portfolio spanning sleep1, epilepsy and oncology. ________________________________ 1 Total sleep revenue includes: Xywav, branded Xyrem and high-sodium oxybate authorized generic royalty revenues. Business Updates Commercial Updates Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution: Xywav net product sales increased 16% to $1,473.2 million in 2024 and increased 19% to $401.0 million in 4Q24 compared to the same periods in 2023. Meaningful Xywav net patient adds in 4Q24 (approximately 525 patients) with approximately 14,150 active Xywav patients exiting 4Q24, comprised of: Approximately 10,250 narcolepsy patients. Approximately 3,900 idiopathic hypersomnia (IH) patients, with 350 net patient adds. Xywav is the only low-sodium oxybate, the #1 branded treatment for narcolepsy2 and the only FDA-approved therapy to treat IH. Approximately 10,250 narcolepsy patients. Approximately 3,900 idiopathic hypersomnia (IH) patients, with 350 net patient adds. Xyrem® (sodium oxybate) oral solution and high-sodium oxybate authorized generic (AG) royalties: Xyrem net product sales decreased 59% to $233.8 million in 2024 and decreased 54% to $49 .3 million in 4Q24 compared to the same periods in 2023. Royalties from high-sodium oxybate AGs increased by $141 .7 million to $217 .6 million in 2024 and increased $15 .9 million to $55 .3 million in 4Q24, compared to the same periods in 2023. Epidiolex/Epidyolex® (cannabidiol): Epidiolex/Epidyolex net product sales increased 15% to $972.4 million in 2024 and increased 14% to $275.0 million in 4Q24 compared to the same periods in 2023. Outside of the U.S. , Epidyolex is approved in more than 35 countries. Presented data at the American Epilepsy Society 2024 Annual meeting, including novel findings from the BECOME-LTC, BECOME-TSC and EpiCom studies, demonstrating the meaningful impact of Epidiolex in the treatment of patients with rare epilepsies including benefits of Epidiolex's benefits beyond seizure control. Remain confident in achieving blockbuster status for Epidiolex/Epidyolex in 2025. Rylaze®/Enrylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn): Rylaze/Enrylaze net product sales increased 4% to $410.8 million in 2024 and were in line in 4Q24 compared to the same periods in 2023 despite headwinds from Children's Oncology Group (COG) protocol changes that impacted timing of asparaginase administration. The temporary impact to Rylaze net product sales due to previously announced COG pediatric acute lymphoblastic leukemia (ALL) protocol updates is still expected to normalize by early 2025. Zepzelca (lurbinectedin): Zepzelca net product sales increased 11% to $320.3 million in 2024 and increased 6% to $78.3 million in 4Q24 compared to the same periods in 2023. Based on potentially practice-changing positive results from the Phase 3 IMforte trial, the Company plans to submit a supplemental New Drug Application (sNDA) for Zepzelca's use in combination with Tecentriq as maintenance therapy in first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC) in 1H25. Ziihera (zanidatamab-hrii): Ziihera net product sales were $1.1 million in 2024 and 4Q24 after the initial product launch and availability in December of 2024 following FDA approval in November. Initial positive reception by prescribers with the first patient treated in December. Ziihera added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology. Ziihera added to European Society for Medical Oncology ® (ESMO®) Clinical Practice Guidelines for Biliary Tract Cancers. __________________________ 2 Based on 4Q24 Xywav net product sales. Key Pipeline Highlights Zanidatamab: In 4Q24, announced U.S. FDA granted accelerated approval of Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). The pivotal HERIZON-GEA-01 trial, evaluating zanidatamab in 1L gastroesophageal adenocarcinoma (GEA), is expected to read out in 2H25 based on an updated assessment of progression events. Recruitment for the trial remains on track. Data presented at the San Antonio Breast Cancer Symposium 2024 continued to underscore zanidatamab's potential for patients previously treated with trastuzumab deruxtecan (T-DXd) and showcased the advancement of our clinical program in breast cancer. The Phase 3 EmpowHER-BC-303 trial to evaluate zanidatamab plus chemotherapy or trastuzumab plus chemotherapy in patients with HER2-positive breast cancer whose disease has progressed on previous T-DXd treatment continues to enroll patients. First patient enrolled in the Phase 2 pan-tumor trial to evaluate HER2-positive solid tumors. Financial Highlights Three Months Ended December 31 , Year Ended December 31 , (In thousands, except per share amounts) 2024 2023 2024 2023 Total revenues $ 1,088,173 $ 1,011,935 $ 4,068,950 $ 3,834,204 GAAP net income $ 191,115 $ 94,154 $ 560,120 $ 414,832 Non-GAAP adjusted net income $ 405,863 $ 345,286 $ 1,369,729 $ 1,295,824 GAAP earnings per share $ 3.11 $ 1.42 $ 8.65 $ 6.10 Non-GAAP adjusted EPS $ 6.60 $ 5.02 $ 20.90 $ 18.29 GAAP net income for 2024 was $560.1 million , or $8.65 per diluted share, compared to $414.8 million , or $6.10 per diluted share, for 2023. GAAP net income for 4Q24 was $191.1 million , or $3.11 per diluted share, compared to a GAAP net income of $94.2 million , or $1.42 per diluted share, for 4Q23. Non-GAAP adjusted net income for 2024 was $1,369 .7 million, or $20.90 per diluted share, compared to $1,295 .8 million, or $18.29 per diluted share, for 2023. Non-GAAP adjusted net income for 4Q24 was $405 .9 million, or $6.60 per diluted share, compared to $345 .3 million, or $5.02 per diluted share, for 4Q23. Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release. Total Revenues Three Months Ended December 31 , Year Ended December 31 , (In thousands) 2024 2023 2024 2023 Xywav $ 400,964 $ 337,019 $ 1,473,202 $ 1,272,977 Xyrem 49,290 106,721 233,816 569,730 Epidiolex/Epidyolex 275,047 240,622 972,423 845,468 Sativex 5,173 5,137 18,877 19,668 Total Neuroscience 730,474 689,499 2,698,318 2,707,843 Rylaze/Enrylaze 101,487 101,747 410,846 394,226 Zepzelca 78,328 74,010 320,318 289,533 Defitelio/defibrotide 57,650 51,083 216,565 184,000 Vyxeos 53,247 46,912 162,595 147,495 Ziihera 1,051 — 1,051 — Total Oncology 291,763 273,752 1,111,375 1,015,254 Other 2,974 4,088 11,471 13,846 Product sales, net 1,025,211 967,339 3,821,164 3,736,943 High-sodium oxybate AG royalty revenue 55,307 39,387 217,575 75,918 Other royalty and contract revenues 7,655 5,209 30,211 21,343 Total revenues $ 1,088,173 $ 1,011,935 $ 4,068,950 $ 3,834,204 Total revenues increased 6% in 2024 and 8% in 4Q24 compared to the same periods in 2023. Total neuroscience revenue, including high-sodium oxybate AG royalty revenue, was $2,915 .9 million in 2024, an increase of 5% compared to $2,783.8 million in 2023 and $785 .8 million in 4Q24, an increase of 8% compared to $728.9 million in 4Q23. The increase in 2024 and 4Q24 was due to higher Xywav and Epidiolex/Epidyolex net product sales together with increased high-sodium oxybate AG royalty revenue, partially offset by decreased Xyrem net product sales. Oncology net product sales were $1,111 .4 million in 2024, an increase of 9% compared to $1,015 .3 million in 2023 and $291 .8 million in 4Q24, an increase of 7% compared to $273 .8 million in 2023, and included higher net product sales from Defitelio/defibrotide which increased 18% in 2024 and 13% in 4Q24 and Zepzelca which increased 11% in 2024 and 6% in 4Q24. In 4Q24, Rylaze net product sales were negatively impacted due to an update to the COG pediatric treatment protocols for ALL, which impacts the timing of asparaginase administration. Operating Expenses and Effective Tax Rate Three Months Ended December 31 , Year Ended December 31 , (In thousands, except percentages) 2024 2023 2024 2023 GAAP: Cost of product sales $ 128,713 $ 107,243 $ 445,713 $ 435,577 Gross margin 87.4 % 88.9 % 88.3 % 88.3 % Selling, general and administrative $ 369,287 $ 396,034 $ 1,385,294 $ 1,343,105 % of total revenues 33.9 % 39.1 % 34.0 % 35.0 % Research and development $ 240,500 $ 216,608 $ 884,000 $ 849,658 % of total revenues 22.1 % 21.4 % 21.7 % 22.2 % Acquired in-process research and development $ — $ 18,000 $ 10,000 $ 19,000 Income tax benefit1 $ (57,912) $ (33,089) $ (91,429) $ (119,912) Effective tax rate 1 (43.5) % (53.8) % (19.4) % (40.2) % _________________________ 1. The GAAP income tax benefit increased in the three months ended December 31, 2024 , compared to the same period in 2023, primarily due to patent box benefits recognized in the period and decreased in the year ended December 31, 2024 , compared to the same period in 2023, primarily due to the change in income mix across our jurisdictions, partially offset by patent box benefits. Three Months Ended December 31 , Year Ended December 31 , (In thousands, except percentages) 2024 2023 2024 2023 Non-GAAP adjusted: Cost of product sales $ 86,492 $ 71,238 $ 295,897 $ 269,079 Gross margin 91.6 % 92.6 % 92.3 % 92.8 % Selling, general and administrative $ 323,167 $ 300,520 $ 1,226,724 $ 1,110,948 % of total revenues 29.7 % 29.7 % 30.1 % 29.0 % Research and development $ 220,857 $ 201,107 $ 809,327 $ 784,811 % of total revenues 20.3 % 19.9 % 19.9 % 20.5 % Acquired in-process research and development $ — $ 18,000 $ 10,000 $ 19,000 Income tax expense1 $ 308 $ 20,475 $ 131,307 $ 93,260 Effective tax rate1 0.1 % 5.6 % 8.7 % 6.7 % _________________________ 1. The non-GAAP income tax expense decreased in the three months ended December 31, 2024 , compared to the same period in 2023, primarily due to patent box benefits recognized in the period and increased in the year ended December 31, 2024 , compared to the same period in 2023, due to the change in income mix across our jurisdictions, partially offset by patent box benefits. Changes in operating expenses in 2024 and 4Q24 over the prior year periods are primarily due to the following: Cost of product sales, on a GAAP and non-GAAP adjusted basis, increased in 2024 and 4Q24, compared to the same periods in 2023, primarily due to higher inventory provisions and changes in product mix. Cost of product sales, on a GAAP basis, included lower acquisition accounting inventory fair value step up expense in 2024 as compared to the previous period. Selling, general and administrative (SG&A) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2024 compared to the same period in 2023, primarily due to higher compensation-related expenses, increased investment in sales and marketing and increased litigation costs, partially offset, on a GAAP basis, by costs related to impairment of facility assets and program terminations in 2023. SG&A expenses, on a GAAP basis, decreased in 4Q24 compared to the same period in 2023, primarily due to the impairment of facility assets in 4Q23, partially offset by higher compensation related expenses. SG&A expenses, on a non-GAAP adjusted basis, increased in 4Q24 primarily due to higher compensation-related expenses. Research and development (R&D) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2024 and 4Q24, compared to the same period in 2023, primarily due to increased compensation related expenses and clinical study costs primarily related to zanidatamab, partially offset by reduced costs related to JZP150 and JZP385. Acquired in-process research and development (IPR&D) expense in 2024, on a GAAP and non-GAAP adjusted basis, related to an upfront payment made in connection with our asset purchase and collaboration agreement with Redx Pharma plc . Acquired IPR&D expense in 2023, on a GAAP and non-GAAP adjusted basis, primarily related to an upfront payment made in connection with our licensing and collaboration agreement with Autifony Therapeutics Limited . Cash Flow and Balance Sheet As of December 31, 2024 , cash, cash equivalents and investments were $3.0 billion , and the outstanding principal balance of the Company's long-term debt was $6.2 billion . In addition, the Company had undrawn borrowing capacity under a revolving credit facility of $885.0 million . For the year ended December 31, 2024 , the Company generated $1.4 billion of cash from operations reflecting strong business performance and continued financial discipline. In January 2025 , the Company made a voluntary prepayment of $750.0 million principal amount on the Term Loan B. 2025 Financial Guidance Jazz Pharmaceutical's full year 2025 financial guidance is as follows: (In millions) Guidance Total Revenues $4,150 - $4,400 (In millions, except per share amounts and percentages) GAAP Non-GAAP Gross margin % 88 % 92%1,6 SG&A expenses $1,404 - $1,483 $1,250 - $1,310 2,6 R&D expenses $792 - $851 $720 - $770 3,6 Effective tax rate (5)% - 10% 13% - 15%4,6 Net income $560 - $720 $1,400 - $1,500 5,6 Net income per diluted share $9.15 - $11.50 $22.50 - $24.00 5,6 Weighted-average ordinary shares used in per share calculations 62 - 63 62 - 63 ___________________________ 1. Excludes $135-$155 million of amortization of acquisition-related inventory fair value step-up and $14-$16 million of share-based compensation expense. 2. Excludes $154-$173 million of share-based compensation expense. 3. Excludes $72-$81 million of share-based compensation expense. 4. Excludes 18%-5% from the GAAP effective tax rate of (5)%-10% relating to the income tax effect of adjustments between GAAP net income and non-GAAP adjusted net income, resulting in a non-GAAP adjusted effective tax rate of 13%-15%. 5. Beginning with the 2025 financial guidance presented in this press release, the company will no longer include an adjustment for non-cash interest expense in its non-GAAP adjusted financial measures. Accordingly, any historical non-GAAP adjusted financial measures presented by the company in the future, beginning with the company's earnings press release for the first quarter of 2025, will not include an adjustment for non-cash interest expense. Any comparative historical periods presented will also be updated to reflect this change beginning with the company's earnings press release for the first quarter of 2025. However, for purposes of comparability with the company's prior presentations of non-GAAP financial measures, the historical non-GAAP financial measures presented in this press release include an adjustment for non-cash interest expense. 6. See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the table titled "Reconciliation of GAAP to non-GAAP Adjusted 2025 Net Income Guidance" at the end of this press release. Conference Call Details Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. ET ( 9:30 p.m. GMT ) to provide a business and financial update and discuss its 2024 full year and 4Q24 results and 2025 guidance. Audio webcast/conference call: U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 5080203 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information. Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this press release and the accompanying tables. In particular, the Company presents non-GAAP adjusted net income (and the related per share measure) and its line-item components, as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP adjusted net income (and the related per share measure) and its line-item components exclude from GAAP reported net income (and the related per share measure) and its line-item components certain items, as detailed in the reconciliation tables that follow, and in the case of non-GAAP adjusted net income (and the related per share measure), adjust for the income tax effect of the non-GAAP adjustments. In this regard, the components of non-GAAP adjusted net income, including non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income measure. The Company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the Company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the Company's results from period to period, to its forward-looking guidance, and to identify operating trends in the Company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the Company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the Company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals' management, the Company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the Company uses in assessing its own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. In this regard, the company has determined that, beginning with the 2025 financial guidance presented in this press release, it will no longer include an adjustment for non-cash interest expense in its non-GAAP adjusted financial measures. Accordingly, any historical non-GAAP adjusted financial measures presented by the company in the future, beginning with the company's earnings press release for the first quarter of 2025, will not include an adjustment for non-cash interest expense. Any comparative historical periods presented will also be updated to reflect this change beginning with the company's earnings press release for the first quarter of 2025. However, for purposes of comparability with the company's prior presentations of non-GAAP financial measures, the historical non-GAAP financial measures presented in this press release include an adjustment for non-cash interest expense. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Caution Concerning Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the Company's 2025 financial guidance and the Company's expectations related thereto and anticipated catalysts; expectations that Xywav will remain the #1 branded treatment for narcolepsy and Epidiolex achieving blockbuster status in 2025; the ability to generate growth and long-term shareholder value; the Company's advancement of pipeline programs and the timing of development activities, regulatory activities and submissions related thereto, including plans to submit a sNDA for Zepzelca in 1L ES-SCLC in the first half of 2025; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, including: top-line PFS data from a Phase 3 trial of zanidatamab in 1L GEA; and the Company's development, regulatory and commercialization strategy; the Company's expectations with respect to its products and product candidates and the potential of the Company's products and product candidates and the potential regulatory path related thereto, including Zepzelca's potential to change current practice in 1L ES-SCLC; the Company's capital allocation and corporate development strategy; the potential successful future development, manufacturing, regulatory and commercialization activities; the Company's ability to realize the commercial potential of its products; the Company's net product sales and goals for net product sales from new and acquired products; the Company's views and expectations relating to its patent portfolio, including with respect to expected patent protection, as well as expectations with respect to exclusivity; the Company's clinical trials confirming clinical benefit or enabling regulatory submissions; planned or anticipated regulatory submissions and filings, and the anticipated timing thereof; potential regulatory approvals; and other statements that are not historical facts. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward- looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of, and revenue from, Xywav, Rylaze and Epidiolex/Epidyolex and other marketed products; the introduction of new products into the U.S. market that compete with, or otherwise disrupt the market for the Company's products and product candidates; effectively launching and commercializing the Company's other products and product candidates; the successful completion of development and regulatory activities with respect to the Company's product candidates, obtaining and maintaining adequate coverage and reimbursement for the Company's products; the time-consuming and uncertain regulatory approval process, including the risk that the Company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the Company's business operations and financial results; geopolitical events, including international tariffs and the conflict between Russia and Ukraine and related sanctions; macroeconomic conditions, including global financial markets, rising interest rates and inflation and recent and potential banking disruptions; regulatory initiatives and changes in tax laws; market volatility; protecting and enhancing the Company's intellectual property rights and the Company's commercial success being dependent upon the Company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the Company's products and product candidates; complying with applicable U.S. and non- U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired product candidates, products and businesses; the Company's ability to realize the anticipated benefits of its corporate development transactions and its collaborations and license agreements with third parties; the sufficiency of the Company's cash flows and capital resources; the Company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the Company's ability to meet its projected long-term goals and objectives, in the time periods that the Company anticipates, or at all, and the inherent uncertainty and significant judgments and assumptions underlying the Company's long-term goals and objectives; fluctuations in the market price and trading volume of the Company's ordinary shares; the timing and availability of alternative investment opportunities; and other risks and uncertainties affecting the Company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024 , and future filings and reports by the Company. Other risks and uncertainties of which the Company is not currently aware may also affect the Company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. JAZZ PHARMACEUTICALS PLC CONDENSED CONSOLIDATED STATEMENTS OF INCOME(In thousands, except per share amounts)(Unaudited) Three Months Ended December 31 , Year Ended December 31 , 2024 2023 2024 2023 Revenues: Product sales, net $ 1,025,211 $ 967,339 $ 3,821,164 $ 3,736,943 Royalties and contract revenues 62,962 44,596 247,786 97,261 Total revenues 1,088,173 1,011,935 4,068,950 3,834,204 Operating expenses: Cost of product sales (excluding amortization of acquired developed technologies) 128,713 107,243 445,713 435,577 Selling, general and administrative 369,287 396,034 1,385,294 1,343,105 Research and development 240,500 216,608 884,000 849,658 Intangible asset amortization 158,903 151,553 627,313 608,284 Acquired in-process research and development — 18,000 10,000 19,000 Total operating expenses 897,403 889,438 3,352,320 3,255,624 Income from operations 190,770 122,497 716,630 578,580 Interest expense, net (51,256) (70,324) (238,097) (289,438) Foreign exchange gain (loss) (6,295) 9,353 (8,182) 8,787 Income before income tax benefit and equity in loss ofinvestees 133,219 61,526 470,351 297,929 Income tax benefit (57,912) (33,089) (91,429) (119,912) Equity in loss of investees 16 461 1,660 3,009 Net income $ 191,115 $ 94,154 $ 560,120 $ 414,832 Net income per ordinary share: Basic $ 3.16 $ 1.50 $ 9.06 $ 6.55 Diluted $ 3.11 $ 1.42 $ 8.65 $ 6.10 Weighted-average ordinary shares used in per share calculations - basic 60,538 62,578 61,838 63,291 Weighted-average ordinary shares used in per share calculations - diluted 61,503 69,673 66,007 72,066 JAZZ PHARMACEUTICALS PLC CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited) December 31 ,2024 December 31 ,2023 ASSETS Current assets: Cash and cash equivalents $ 2,412,864 $ 1,506,310 Investments 580,000 120,000 Accounts receivable, net of allowances 716,765 705,794 Inventories 480,445 597,039 Prepaid expenses 177,411 185,476 Other current assets 261,543 320,809 Total current assets 4,629,028 3,435,428 Property, plant and equipment, net 173,413 169,646 Operating lease assets 53,582 65,340 Intangible assets, net 4,755,695 5,418,039 Goodwill 1,716,323 1,753,130 Deferred tax assets, net 560,245 477,834 Deferred financing costs 9,489 6,478 Other non-current assets 114,482 67,464 Total assets $ 12,012,257 $ 11,393,359 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 77,869 $ 102,750 Accrued liabilities 910,947 793,914 Current portion of long-term debt 31,000 604,954 Income taxes payable 18,757 35,074 Total current liabilities 1,038,573 1,536,692 Long-term debt, less current portion 6,077,640 5,107,988 Operating lease liabilities, less current portion 38,938 59,225 Deferred tax liabilities, net 676,736 847,706 Other non-current liabilities 86,614 104,751 Total shareholders' equity 4,093,756 3,736,997 Total liabilities and shareholders' equity $ 12,012,257 $ 11,393,359 JAZZ PHARMACEUTICALS PLC SUMMARY OF CASH FLOWS (In thousands)(Unaudited) Year Ended December 31 , 2024 2023 Net cash provided by operating activities $ 1,395,908 $ 1,092,007 Net cash used in investing activities (508,195) (163,062) Net cash provided by (used in) financing activities 20,516 (305,254) Effect of exchange rates on cash and cash equivalents (1,675) 1,137 Net increase in cash and cash equivalents $ 906,554 $ 624,828 JAZZ PHARMACEUTICALS PLC RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION(In thousands, except per share amounts)(Unaudited) Three Months Ended December 31 , Year Ended December 31 , 2024 2023 2024 2023 Net Income DilutedEPS1 Net Income Diluted EPS1 NetIncome DilutedEPS1 NetIncome Diluted EPS1 GAAP reported $ 191,115 $ 3.11 $ 94,154 $ 1.42 $ 560,120 $ 8.65 $ 414,832 $ 6.10 Intangible asset amortization 158,903 2.58 151,553 2.18 627,313 9.50 608,284 8.44 Share-based compensation expense 70,190 1.14 52,941 0.76 248,045 3.76 226,841 3.15 Acquisition accountinginventory fair value step-up 37,794 0.61 32,352 0.46 135,014 2.05 151,446 2.10 Other costs2 — — 61,727 0.89 — — 85,215 1.18 Non-cash interest expense3 6,081 0.10 6,123 0.09 21,973 0.33 22,378 0.31 Income tax effect of above adjustments (58,220) (0.94) (53,564) (0.77) (222,736) (3.37) (213,172) (2.95) Effect of assumed conversion of the 2024 Notes and the2026 Notes1 — — — (0.01) — (0.02) — (0.04) Non-GAAP adjusted $ 405,863 $ 6.60 $ 345,286 $ 5.02 $ 1,369,729 $ 20.90 $ 1,295,824 $ 18.29 Weighted-average ordinaryshares used in diluted per share calculations - GAAP and non-GAAP1 61,503 69,673 66,007 72,066 ________________________________________________ Explanation of Adjustments and Certain Line Items: 1. Diluted EPS was calculated using the "if-converted" method in relation to the 1.50% exchangeable senior notes due 2024, or the 2024 Notes and the 2.000% exchangeable senior notes due 2026, or the 2026 Notes. In August 2023 and July 2024 , we made irrevocable elections to net share settle the 2024 Notes and the 2026 Notes, respectively. As a result, the assumed issuance of ordinary shares upon exchange of the 2024 Notes and the 2026 Notes have only been included in the calculation of diluted net income per ordinary share, on a GAAP and on a non-GAAP adjusted basis, in each period up to the date each irrevocable election was made. Net income per diluted share, on a GAAP and on a non-GAAP adjusted basis, for the year ended December 31, 2024 , included 3.5 million shares related to the assumed conversion of the 2026 Notes and the associated interest expense, net of tax, add-back to GAAP reported net income and non-GAAP adjusted net income of $10.8 million and $9.7 million , respectively. Net income per diluted share, on a GAAP and on a non-GAAP adjusted basis, for the three months and the year ended December 31, 2023 included 6.4 million shares and 8.0 million shares, respectively, related to the assumed conversion of the 2024 Notes and the 2026 Notes and the associated interest expense, net of tax, add-back to GAAP reported net income of $4.9 million and $24.9 million , respectively, and the associated interest expense, net of tax, add-back to non-GAAP adjusted net income of $4.4 million and $22.2 million , respectively. 2. Includes costs related to the impairment of facility assets and program terminations. 3. Non-cash interest expense associated with debt issuance costs. JAZZ PHARMACEUTICALS PLC RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATIONCERTAIN LINE ITEMS - FOR THE THREE MONTHS ENDED DECEMBER 31, 2024 AND 2023(In thousands, except percentages)(Unaudited) Three months ended December 31, 2024 Cost ofproductsales Grossmargin Selling, general andadministrative Researchanddevelopment Intangible assetamortization Interestexpense, net Income tax expense (benefit) Effectivetax rate GAAP Reported $ 128,713 87.4 % $ 369,287 $ 240,500 $ 158,903 $ 51,256 $ (57,912) (43.5) % Non-GAAP Adjustments: Intangible asset amortization — — — — (158,903) — — — Share-based compensationexpense (4,427) 0.5 (46,120) (19,643) — — — — Acquisition accountinginventory fair value step-up (37,794) 3.7 — — — — — — Non-cash interest expense — — — — — (6,081) — — Income tax effect of above adjustments — — — — — — 58,220 43.6 Total of non-GAAP adjustments (42,221) 4.2 (46,120) (19,643) (158,903) (6,081) 58,220 43.6 Non-GAAP Adjusted $ 86,492 91.6 % $ 323,167 $ 220,857 $ — $ 45,175 $ 308 0.1 % Three months ended December 31, 2023 Cost ofproductsales Gross margin Selling, general and administrative Research anddevelopment Intangibleassetamortization AcquiredIPR&D Interest expense, net Income tax expense(benefit) Effective tax rate GAAP Reported $ 107,243 88.9 % $ 396,034 $ 216,608 $ 151,553 $ 18,000 $ 70,324 $ (33,089) (53.8) % Non-GAAP Adjustments: Intangible asset amortization — — — — (151,553) — — — — Share-based compensationexpense (3,653) 0.4 (33,787) (15,501) — — — — — Restructuring and othercosts — — (61,727) — — — — — — Non-cash interest expense — — — — — — (6,123) — — Acquisition accountinginventory fair value step-up (32,352) 3.3 — — — — — — — Income tax effect of aboveadjustments — — — — — — — 53,564 59.4 Total of non-GAAP adjustments (36,005) 3.7 (95,514) (15,501) (151,553) — (6,123) 53,564 59.4 Non-GAAP Adjusted $ 71,238 92.6 % $ 300,520 $ 201,107 $ — $ 18,000 $ 64,201 $ 20,475 5.6 % JAZZ PHARMACEUTICALS PLC RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATIONCERTAIN LINE ITEMS - FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023(In thousands, except percentages)(Unaudited) Year ended December 31, 2024 Cost of product sales Gross margin Selling, general andadministrative Research and development Intangible assetamortization AcquiredIPR&D Interest expense, net Income tax expense(benefit) Effective tax rate GAAP Reported $ 445,713 88.3 % $ 1,385,294 $ 884,000 $ 627,313 $ 10,000 $ 238,097 $ (91,429) (19.4) % Non-GAAP Adjustments: Intangible asset amortization — — — — (627,313) — — — — Share-based compensation expense (14,802) 0.5 (158,570) (74,673) — — — — — Non-cash interest expense — — — — — — (21,973) — — Acquisition accounting inventory fairvalue step-up (135,014) 3.5 — — — — — — — Income tax effect of above adjustments — — — — — — — 222,736 28.1 Total of non-GAAP adjustments (149,816) 4.0 (158,570) (74,673) (627,313) — (21,973) 222,736 28.1 Non-GAAP Adjusted $ 295,897 92.3 % $ 1,226,724 $ 809,327 $ — $ 10,000 $ 216,124 $ 131,307 8.7 % Year ended December 31, 2023 Cost ofproduct sales Gross margin Selling, general and administrative Research and development Intangible asset amortization AcquiredIPR&D Interest expense, net Income tax expense (benefit) Effective tax rate GAAP Reported $ 435,577 88.3 % $ 1,343,105 $ 849,658 $ 608,284 $ 19,000 $ 289,438 $ (119,912) (40.2) % Non-GAAP Adjustments: Intangible asset amortization — — — — (608,284) — — — — Share-based compensation expense (15,052) 0.4 (146,942) (64,847) — — — — — Other costs — — (85,215) — — — — — — Non-cash interest expense — — — — — — (22,378) — — Acquisition accounting inventory fair value step-up (151,446) 4.1 — — — — — — — Income tax effect of above adjustments — — — — — — — 213,172 46.9 Total of non-GAAP adjustments (166,498) 4.5 (232,157) (64,847) (608,284) — (22,378) 213,172 46.9 Non-GAAP Adjusted $ 269,079 92.8 % $ 1,110,948 $ 784,811 $ — $ 19,000 $ 267,060 $ 93,260 6.7 % JAZZ PHARMACEUTICALS PLC RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2025 NET INCOME AND DILUTED EPS GUIDANCE(In millions, except per share amounts)(Unaudited) Net Income Diluted EPS GAAP guidance $560 - $720 $9.15 - $11.50 Intangible asset amortization 610 - 660 9.70 - 10.60 Acquisition accounting inventory fair value step-up 135 - 155 2.15 - 2.50 Share-based compensation expense 240 - 270 3.80 - 4.35 Income tax effect of above adjustments (215) - (235) (3.40) - (3.75) Non-GAAP guidance $1,400 - $1,500 $22.50 - $24.00 Weighted-average ordinary shares used in per share calculations - GAAP and non-GAAP 62 - 63 Contacts: Investors: Jeff Macdonald Executive Director, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717 Media: Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc CorporateAffairsMediaInfo@jazzpharma.com Ireland +353 1 637 2141 U.S. +1 215 867 4948 View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2024-financial-results-and-provides-2025-financial-guidance-302385001.html SOURCE Jazz Pharmaceuticals plc

Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) expected in Q3 2024 PRAX-628 Phase 2/3 POWER1 study to initiate in Q4 2024 Initiation of additional Phase 2 study (RADIANT) for PRAX-628 in focal and generalized epilepsy in 2H 2024, with topline results expected in 1H 2025 Cash and investments of $434 million as of June 30, 2024, maintains runway into 2027 BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter 2024. “In the second quarter we continued to advance our entire portfolio, and we are poised to soon have up to four programs in registrational stage. The Essential3 program continues to progress well, with a pre-planned interim analysis of Study 1 to be conducted later this year. We remain on track for a successful topline readout enabling an NDA filing in 2025,” said Marcio Souza, president and chief executive officer of Praxis. “We look forward to sharing topline results of the EMBOLD study for relutrigine, formerly known as PRAX-562, in SCN2A and 8A patients later this quarter and believe these indications could be the tip of the iceberg for future application of PRAX-562 in other DEEs.” Mr. Souza added, “We are also excited to build on the encouraging data generated to date with PRAX-628 by executing on the ENERGY program, a comprehensive set of studies, including a new Phase 2 study (RADIANT), with topline data expected in the first half of 2025 in focal and generalized epilepsy. Additionally, with elsunersen having initiated the first arm of its global confirmatory study in Brazil, we anticipate the rapid advancement of all four clinical programs in our portfolio towards regulatory registrations. Our strong cash position, which fully funds Praxis through several important readouts into 2027, enables this momentum.” Recent Highlights and Anticipated Milestones: Cerebrum™ Small Molecule Platform Ulixacaltamide for ET: Topline results of two studies in the Essential3 Phase 3 program for ulixacaltamide are expected in the second half of 2024 to support a planned New Drug Application (NDA) submission in 2025. Since beginning recruitment in November 2023, there have been over 75,000 pre-screening forms, of which 11,000 referrals meet pre-qualifying eligibility criteria.Praxis to conduct an interim analysis for Study 1 in the Essential3 program in the fourth quarter of 2024. This pre-planned analysis is part of the original statistical plan and protocol for Essential3.Long-term safety study enrollment criteria have been expanded to include patients who participated in previous ET studies, including previous suvecaltamide trials. PRAX-628 for Epilepsy: Praxis expects to initiate four studies as part of the PRAX-628 ENERGY program, aiming to generate efficacy, safety and pharmacokinetics (PK) data to serve as the basis of regulatory registrations globally. EMPOWER is an observational study in partnership with the Epilepsy Consortium expected to start in the third quarter of 2024, aiming to enroll patients with epilepsy to better characterize seizure burdenRADIANT is a Phase 2 PK, safety and efficacy study in patients with focal onset seizures (FOS) or generalized epilepsy expected to start in the second half of 2024, with topline results in the first half of 2025POWER1 and POWER2 are 12-week Phase 2/3 studies in patients with FOS aiming to show efficacy of PRAX-628. POWER1 is expected to start enrolling patients in the fourth quarter of 2024, with topline results in the second half of 2025. POWER2 is expected to start enrolling patients in the first half of 2025. Relutrigine (PRAX-562) for SCN2A and SCN8A DEEs: Praxis expects topline results from the Phase 2 EMBOLD study for the treatment of pediatric patients with DEEs in the third quarter of 2024. The EMBOLD study is a Phase 2 study evaluating the safety, tolerability, efficacy (motor seizure frequency) and PK of relutrigine in pediatric patients aged 2 to 18 years with DEEs, followed by an open-label extension.Based on results for the EMBOLD study, Praxis expects to consider a more expansive program of relutrigine in all DEEs with high seizure burden. Solidus™ Antisense Oligonucleotide (ASO) Platform Elsunersen (PRAX-222) for early-seizure-onset SCN2A Developmental Epilepsies First arm of the global confirmatory study initiated in BrazilPivotal phase of the program remains on track, and Praxis plans to advance the program within the US and expand to Europe later in 2024. Second Quarter 2024 Financial Results: As of June 30, 2024, Praxis had $433.8 million in cash, cash equivalents, and marketable securities, compared to $81.3 million in cash and cash equivalents as of December 31, 2023. The increase of $352.5 million is primarily due to net proceeds from Praxis’ January 2024 and April 2024 follow-on public offerings plus net proceeds from at-the-market sales of common stock, offset by cash used in operating activities. Praxis recognized $0.4 million in collaboration revenue during the three months ended June 30, 2024, compared to $0.8 million during the three months ended June 30, 2023. The decrease of $0.4 million is associated with a decrease in revenue recorded under the UCB Collaboration Agreement. Research and development expenses were $27.3 million for the three months ended June 30, 2024, compared to $25.6 million for the three months ended June 30, 2023. The increase in research and development expenses of $1.6 million was primarily attributable to an increase of $8.1 million in Praxis’ Cerebrum™ platform and a $1.7 million increase in personnel-related costs, primarily offset by a $8.2 million decrease in costs associated with Praxis’ Solidus™ platform. General and administrative expenses were $10.6 million for the three months ended June 30, 2024, compared to $10.1 million for the three months ended June 30, 2023. The increase in general and administrative expenses of approximately $0.5 million was primarily due to increased personnel-related costs. Praxis reported a net loss of $32.7 million for the three months ended June 30, 2024, including $5.9 million of stock-based compensation expense, compared to $34.3 million for the three months ended June 30, 2023, including $5.8 million of stock-based compensation. As of June 30, 2024, Praxis had 17.8 million shares of common stock outstanding. Conference Call Praxis Precision Medicines will host a conference call and webcast today at 8:00 a.m. ET to review the second quarter 2024 financial results and recent business highlights. Individuals may register for the conference call by clicking the registration link. Once registered, participants will receive dial-in details and a unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.praxismedicines.com. Following the live webcast, an archived replay will also be available. About UlixacaltamideUlixacaltamide is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated with tremor activity. Ulixacaltamide, the most advanced program within Praxis’ Cerebrum™ small molecule platform, is currently in late-stage development for the treatment of essential tremor, www.praxisessentialtremor.com. About PRAX-628PRAX-628 is a next-generation, functionally selective small molecule targeting the hyperexcitable state of sodium-channels in the brain that is currently being developed as a once daily, oral treatment for adult focal onset epilepsy. Preclinical data demonstrates PRAX-628 is differentiated from standard of care, with the potential to be best-in-class for focal epilepsy. In vitro, PRAX-628 has demonstrated superior selectivity for disease-state NaV channel hyperexcitability. In vivo studies of PRAX-628 have demonstrated unprecedented potency in the maximal electroshock seizure (MES) model, a highly predictive translational model for efficacy in focal epilepsy. Data from the PRAX-628-101 study demonstrated that PRAX-628 can be safely dosed in healthy subjects to greater than 15 times the predicted human equivalent of the rodent MES EC50. About Elsunersen (PRAX-222)Elsunersen is an antisense oligonucleotide (ASO) designed to selectively decrease SCN2A gene expression, directly targeting the underlying cause of early-seizure-onset SCN2A-DEE to treat seizures and other symptoms in patients with gain-of-function SCN2A mutations. In vitro studies of elsunersen have demonstrated reduction in both SCN2A gene expression and protein levels. In vivo, elsunersen has demonstrated significant, dose-dependent reduction in seizures, improvement in behavioral and locomotor activity and increased survival in SCN2A mouse models, with potential to be the first disease-modifying treatment for SCN2A-DEE. Elsunersen has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPD) from the FDA, and ODD and PRIME designations from the European Medicines Agency (EMA) for the treatment of SCN2A-DEE. The Elsunersen program is ongoing under a collaboration with Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), and RogCon, Inc. To learn more about the EMBRAVE study, please visit https://www.embravestudy.com/. About Relutrigine (PRAX-562)Relutrigine is a first-in-class small molecule in development for the treatment of developmental and epileptic encephalopathy (DEE) as a preferential inhibitor of persistent sodium current, shown to be a key driver of seizure symptoms in early onset SCN2A-DEE and SCN8A-DEE. Relutrigine’s mechanism of sodium channel blocking is consistent with superior selectivity for disease state sodium channel (NaV) channel hyperexcitability. In vivo studies of relutrigine have demonstrated dose-dependent inhibition of seizures up to complete control of seizure activity in SCN2A, SCN8A and other DEE mouse models. Relutrigine has been generally well-tolerated in three Phase 1 studies and has demonstrated biomarker changes indicative of NaV channel blocking effects. Relutrigine has received ODD and RPD from the FDA, and ODD from the European Medicines Agency for the treatment of SCN2A-DEE and SCN8A-DEE. To learn more about the EMBOLD study, please visit https://www.emboldstudy.org/. About PraxisPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis’ future expectations, plans and prospects, including, without limitation, statements regarding the anticipated timing of our clinical trials, the development of our product candidates, the anticipated timing of regulatory submissions and interactions and our projected cash runway, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical trials; preliminary analyses from ongoing studies differing materially from final data from preclinical studies and completed clinical trials; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials; and other risks concerning Praxis’ programs and operations as described in its Annual Report on Form 10-K for the year ended December 31, 2023 and other filings made with the Securities and Exchange Commission. Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. PRAXIS PRECISION MEDICINES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in thousands)(Unaudited) June 30, 2024 December 31, 2023Assets Cash and cash equivalents$145,143 $81,300 Marketable securities 288,688 — Prepaid expenses and other current assets 4,837 3,580 Property and equipment, net 369 588 Operating lease right-of-use assets 1,610 2,064 Other non-current assets 416 416 Total assets$441,063 $87,948 Liabilities and stockholders’ equity Accounts payable$8,195 $5,815 Accrued expenses 10,058 7,416 Operating lease liabilities 1,946 2,495 Deferred revenue 1,764 2,553 Common stock 14 13 Additional paid-in capital 1,145,308 723,577 Accumulated other comprehensive loss (71) — Accumulated deficit (726,151) (653,921)Total liabilities and stockholders' equity$441,063 $87,948 PRAXIS PRECISION MEDICINES, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except share and per share amounts)(Unaudited) Three Months Ends June 30, Six Months Ended June 30, 2024 2023 2024 2023 Collaboration revenue$357 $781 $788 $1,464 Operating expenses: Research and development 27,260 25,614 54,244 51,118 General and administrative 10,585 10,127 25,918 23,397 Total operating expenses 37,845 35,741 80,162 74,515 Loss from operations (37,488) (34,960) (79,374) (73,051)Other income: Other income, net 4,811 648 7,144 1,284 Total other income 4,811 648 7,144 1,284 Net loss$(32,677) $(34,312) $(72,230) $(71,767)Net loss per share attributable to common stockholders, basic and diluted$(1.74) $(7.38) $(4.41) $(17.51)Weighted average common shares outstanding, basic and diluted 18,824,479 4,649,371 16,364,421 4,097,833